Lilly Sees New Weight-Loss Pill Approval in Early 2026, CEO Says

1 day ago · Eli Lilly & Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, Chief Executive Officer Dave Ricks said, one of several in a new generation of the popular drugs.

$2
OFF

Eli Lilly CEO On Fighting Cancer And Obesity, Drug Pricing

2 weeks from now

1 day ago · Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental …

bloomberg.com

$13
OFF

Eli Lilly Exec On Weight-loss Drugs: 'It's Not Just A Flash In The Pan'

2 weeks from now

Jun 10, 2024 · Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024 — …

yahoo.com

$1.26
OFF

Eli Lilly’s Slip Does Not Mean The Weight Loss Drug Craze Is Over

2 weeks from now

Oct 30, 2024 · Zepbound, a weight-loss injection that was only approved last year, generated $1.26bn in sales, below the $1.69bn predicted. The misses are largely down to inventory …

ft.com

$120
OFF

Lilly Loses $120 Billion In Value As Rival Obesity Drugs Impress

2 weeks from now

Jul 25, 2024 · (Bloomberg) -- Eli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals …

bnnbloomberg.ca

7%
OFF

Eli Lilly Shares Tumble After Cutting Its Sales Outlook. What It Means ...

2 weeks from now

15 hours ago · Shares plunged 7% after management said demand for its popular GLP-1 drugs did not meet expectations.

cnbc.com

$13
OFF

Eli Lilly Sees Growth In 2025 From New Medicines

2 weeks from now

1 day ago · Eli Lilly sees Q4 worldwide revenue ~$13.5B, consensus $13.95B; Eli Lilly (LLY) Expects Weight-Loss Pill Approval in 2026; Eli Lilly CEO tells Bloomberg TV company sees …

businessinsider.com

$58
OFF

Eli Lilly Sees FY25 Revenue $58B-$61B, Consensus $58.48B

2 weeks from now

1 day ago · Eli Lilly (LLY) Expects Weight-Loss Pill Approval in 2026; Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026; Eli Lilly to acquire Scorpion …

businessinsider.com

FAQs about Lilly Sees New Weight-Loss Pill Approval in Early 2026, CEO Says Coupon?

Is Eli Lilly expanding its medicine supply?

Eli Lilly chairman and CEO Dave Ricks says the company is working on expanding its medicine supply as the global obesity rate increases. Speaking with Bloomberg's Caroline Hyde at the Economic Club of New York, Ricks says the company is looking to create an oral tablet in addition to an injectable device and hopes to get them to market quicker. ...

Is Eli Lilly a poster child of the weight-loss drug frenzy?

(Bloomberg) -- Eli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals posting encouraging developments for their obesity treatments. The company’s shares fell as much as 6.2% on Thursday, hitting the lowest intraday level since May. ...

Is Eli Lilly a good stock to buy?

Eli Lilly’s chunky valuation means it has little room for error. The shares have more than tripled since the start of 2022 to make the company the world’s most valuable drugmaker. Thanks to the frenzy for its weight-loss drugs, it had at its peak last month a market capitalisation of over $860bn. ...

Why did Eli Lilly drop 11 per cent in pre-market trading?

The stock tumbled by as much as 11 per cent in pre-market trading after Eli Lilly reported quarterly sales for its key GLP-1 drugs — Mounjaro and Zepbound — that missed analysts’ estimates. After raising its guidance twice this year, Eli Lilly now expects full year sales to top out at $46bn, compared with its previous guidance of $46.6bn. ...

Why did Eli Lilly stock tumble 11 per cent in pre-market trading?

That appears to be what happened on Wednesday. The stock tumbled by as much as 11 per cent in pre-market trading after Eli Lilly reported quarterly sales for its key GLP-1 drugs — Mounjaro and Zepbound — that missed analysts’ estimates. ...

Why did Eli Lilly miss a quarter?

The misses are largely down to inventory issues, rather than weaker demand. Until recently, Eli Lilly had struggled to produce enough Mounjaro and Zepbound to meet demand. A ramp-up in manufacturing capacity finally allowed it to fill back-orders and improve wholesaler supplies during the second quarter. ...